VANCOUVER , March 13, 2019 /CNW/ - Village Farms International, Inc. ("Village Farms" or the "Company") (VFF) (VFF) today announced its financial results for the fourth quarter and year ended December 31, 2018 .
Financial and Corporate Highlights for the
Fourth Quarter Ended December 31, 2018
(All comparable
figures are for the fourth quarter ended December 31, 2017
)
Financial Highlights for the Year Ended
December 31, 2018
(All comparable figures are for the
year ended December 31, 2017 )
Summary of Recent Highlights for Village Farms' Canadian Cannabis Joint Venture, Pure Sunfarms
Highlights for Village Farms' U.S. Hemp/CBD Initiative
"It is a remarkable achievement for Pure Sunfarms' to not only generate positive net income in just its first full quarter of sales but for Pure Sunfarms to be profitable for the entire year, during most of which the Pure Sunfarms greenhouse was in the process of being converted for cannabis production," said Michael DeGiglio , Chief Executive Officer, Village Farms. "It is demonstrative of the value that Village Farms, with its 30-years of experience as a large-scale, low-cost developer and grower, brings to the Pure Sunfarms joint venture, as well as the advantage of pursuing the Canadian cannabis opportunity via an established, high-performance greenhouse operation with more than 750 years of combined grower experience, an experienced skilled labour force already in place, and the benefit of years of operating history across multiple crops in multiple regions around the world."
"Pure Sunfarms is positioned for earnings growth throughout 2019 and beyond as it ramps to full run rate annual production of 75,000 kilograms by mid-year, commences sales to the Ontario Cannabis Store upon receipt of its processing and packaging licenses, and redirects sales to the retail market following conclusion of its supply agreement with Emerald Health Therapeutics at the end of this year. To this end, Pure Sunfarms is steadily advancing its product and brand strategies to realize its vision to be a premier vertically integrated supplier to the Canadian cannabis market, with a reputation for quality, consistency, safety and reliability."
"In the United States , with hemp cultivation and hemp products now federally legal, we are aggressively pursuing a vertically integrated hemp-derived CBD strategy to capitalize on this significant opportunity. We have already taken a major step in this regard with the formation of a joint venture for outdoor hemp cultivation and CBD extraction, Village Fields Hemp, with an experienced partner, and expect to begin generating revenue later this year. With 5.7 million square feet of existing technologically advanced greenhouse operations in Texas , we stand ready, subject to legalization in Texas , to address what we believe will be significant demand for controlled environment-grown hemp to meet the needs of specific customers. As a vertically integrated produce supplier to North America's top grocery and "big box" retailers for decades, and with in-house expertise to navigate the evolving regulatory environment, Village Farms is very well positioned to become a leading supplier of branded and private label CBD products to these retailers."
Summary Statuary Results
(in thousands of U.S. Dollars unless otherwise
indicated)
For the three months |
For the year ended |
||||||
2018 |
2017 |
2018 |
2017 |
||||
Sales |
$38,787 |
$36,864 |
$150,000 |
$158,406 |
|||
Cost of sales |
(36,367) |
(31,908) |
(140,282) |
(144,433) |
|||
Selling, general and administrative expenses |
(3,622) |
(4,019) |
(14,108) |
(13,894) |
|||
Stock compensation expense |
(1,007) |
(959) |
(1,454) |
(1,519) |
|||
Change in biological asset(1) |
158 |
1,082 |
(843) |
265 |
|||
Interest expense, net |
(501) |
(679) |
2,407 |
2,695 |
|||
Other income |
(70) |
(50) |
(131) |
46 |
|||
Foreign exchange (loss) gain |
(960) |
(31) |
(1,047) |
26 |
|||
Share of income (loss) from joint venture |
2,750 |
(35) |
2,381 |
(255) |
|||
Income (loss) on disposal of assets |
- |
(551) |
- |
8,013 |
|||
(Recovery of) provision for income taxes |
(962) |
(321) |
(2,475) |
138 |
|||
Net income (loss) |
270 |
(607) |
(5,145) |
3,822 |
|||
EBITDA(2) |
1,484 |
2,591 |
$2,878 |
$7,363 |
|||
Earnings (loss) per share â basic and diluted |
$0.01 |
($0.02) |
($0.11) |
$0.10 |
Summary Results Including Pure Sunfarms on a Proportionate Basis
The following results reflect the Company's proportionate share of the Pure Sunfarms joint venture operations, as this is the basis on which management bases its operating decisions and performance. For a reconciliation to the results in accordance with International Financial Reporting Standards ("IFRS") refer to the "Reconciliation of IFRS to Proportionate Results" as presented below and in Management's Discussion & Analysis ("MD&A").
(in thousands of U.S. Dollars unless otherwise indicated)
For the three months ended |
For the year ended |
||||||
20181 |
20171 |
20181 |
20171 |
||||
Sales |
$40,590 |
$36,864 |
$151,913 |
$158,406 |
|||
Cost of sales |
(36,896) |
(31,908) |
(140,882) |
(144,433) |
|||
Selling, general and administrative expenses |
(4,113) |
(4,147) |
(15,414) |
(14,242) |
|||
Change in biological asset (2) |
3,120 |
1,082 |
2,552 |
265 |
|||
Net income (loss) |
270 |
(607) |
(5,145) |
3,822 |
|||
EBITDA(3) |
$1,484 |
$2,591 |
$2,878 |
$7,363 |
|||
Earning (loss) per share â basic and diluted |
$0.01 |
($0.02) |
($0.11) |
$0.10 |
Notes: |
|
(1) |
The consolidated financial results above reflect the proportionate share of the Company's share of revenues and expenses from its joint venture operations, as this is the basis which management bases its operating decisions and performance evaluation. IFRS does not allow for the inclusion of the joint venture on a proportionate basis. These results include additional non-IFRS measures such as EBITDA. |
The results are not generally accepted measures of financial performance under IFRS. The Company's method of calculating these financial performance measures may differ from other companies and accordingly, they may not be comparable to measures used by other companies. Refer to the MD&A for a reconciliation of these non-IFRS measures and proportionate results. |
|
(2) |
Biological assets consist of the Company's produce on the vines and Pure Sunfarms' bud and trim on the plant at the period end. Details of the changes are described in note 6 of the Company's annual consolidated financial statements year ended December 31, 2018. |
(3) |
EBITDA is not a recognized earnings measure and does not have a standardized meaning prescribed by IFRS. Therefore, EBITDA may not be comparable to similar measures presented by other issuers. See "Non-IFRS Measures". Management believes that EBITDA is a useful supplemental measure in evaluating the performance of the Company. Consolidated EBITDA includes the Company's 50% share of its joint venture Pure Sunfarms. |
Financial Highlights
(All amounts in U.S. Dollars unless otherwise indicated.)
Cannabis
Pure Sunfarms commenced sales in late September 2018 ; for the year ended December 31, 2018 the Company's 50% share of sales is $1,897 .
The Company's share of net income for the three months and year ended December 31, 2018 was $2,750 and $2,381 , respectively, Pure Sunfarms was able to achieve net income in its first full quarter of sales.
The Company's share of EBITDA for the three months and year ended December 31, 2018 was $861 and $111 , respectively, Pure Sunfarms was able to achieve a positive EBITDA in its first full quarter of sales.
Vegetable
Sales for the year ended December 31, 2018 decreased (5%) from the year ended December 31, 2017 , the decrease is due to the loss of tomato production from the Delta 3 facility, which was contributed to Pure Sunfarms in 2017 and the Company's lower production at its Texas facilities. Net price for tomato pounds increased 4% for the year ended December 31, 2018 versus the year ended December 31, 2017 due to a higher percent of higher priced tomato production in 2018 as compared to 2017. Pepper prices decreased (2%) over the comparable period in 2017, and cucumber prices decreased (1%) for the years ended December 31, 2018 over the comparable period in 2017.
Cost of sales for the year ended December 31, 2018 decreased (3%) from the year ended December 31, 2017 , primarily due to the loss of the Delta 3 facility and a decrease in costs at the Texas facilities due to a decrease in pounds produced partially offset by an increase of 6% in contract sales cost.
EBITDA for the year period ended December 31, 2018 decreased (62%) from the year period ended December 31, 2017 , primarily as a result of a decrease in income from operations that was caused by the removal of the Delta 3 facility as well as a decrease in production for the Texas facilities. The production shortfall at the Texas facilities resulted in decreased sales and an increase in cost per pound for product produced as the fixed costs were spread over less pounds.
Reconciliation of IFRS to Proportionate Results
The following tables are a reconciliation of the IFRS results to the proportionate results (which include the Company's proportionate share of the Pure Sunfarms operations). Refer to the MD&A for further discussion and analysis of these results:
For the three months ended December 31, 2018 |
For the three months ended December 31, 2017 |
||||||||||
Produce |
Cannabis4 |
Total |
Produce |
Cannabis4 |
Total |
||||||
Sales |
$38,787 |
$1,803 |
$40,590 |
$36,864 |
$- |
$36,864 |
|||||
Cost of sales |
(36,367) |
(529) |
(36,896) |
(31,908) |
- |
(31,908) |
|||||
Selling, general and administrative expenses |
(3,622) |
(491) |
(4,113) |
(4,019) |
(128) |
(4,147) |
|||||
Change in biological asset(5) |
158 |
2,962 |
3,120 |
1,082 |
- |
1,082 |
|||||
(Gain) loss on sale of assets |
- |
- |
- |
(511) |
- |
(511) |
|||||
(Recovery of) provision for income taxes |
(962) |
887 |
(75) |
321 |
(93) |
228 |
|||||
Net (loss) income |
(2,480) |
2,750 |
270 |
(572) |
(35) |
(607) |
|||||
EBITDA(6) |
$623 |
$861 |
$1,484 |
2,720 |
(129) |
2,591 |
|||||
(Loss) earnings per share â basic and diluted |
($0.05) |
$0.06 |
$0.01 |
($0.02) |
$0.00 |
($0.02) |
For the year ended December 31 , 2018 |
For the year ended December 31, 2017 |
|||||||||||||
Produce |
Cannabis4 |
Total |
Produce |
Cannabis4 |
Total |
|||||||||
Sales |
$150,000 |
$1,897 |
$151,913 |
$158,406 |
$- |
$158,406 |
||||||||
Cost of sales |
(140,282) |
(595) |
(140,882) |
(144,433) |
- |
(144,433) |
||||||||
Selling, general and administrative expenses |
(14,108) |
(1,306) |
(15,414) |
(13,894) |
(348) |
(14,242) |
||||||||
Change in biological asset(5) |
(834) |
3,386 |
2,552 |
265 |
- |
265 |
||||||||
(Gain) loss on sale of assets |
- |
- |
- |
(8,013) |
- |
(8,013) |
||||||||
(Recovery of) provision for income taxes |
(2,475) |
887 |
(1,588) |
138 |
94 |
232 |
||||||||
Net (loss) income |
(7,526) |
2,381 |
(5,145) |
4,077 |
(255) |
3,822 |
||||||||
EBITDA(6) |
$2,767 |
$111 |
2,878 |
$7,456 |
($93) |
$7,363 |
||||||||
(Loss) earnings per share â basic and diluted |
($0. |